1999
Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support
Winer E, Lindley C, Hardee M, Sawyer W, Brunatti C, Borstelmann N, Peters W. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. Psycho-Oncology 1999, 8: 167-176. PMID: 10335560, DOI: 10.1002/(sici)1099-1611(199903/04)8:2<167::aid-pon354>3.0.co;2-s.Peer-Reviewed Original ResearchConceptsFunctional Living Index-CancerHigh-dose chemotherapyQuality of lifeAutologous bone marrow supportBone marrow supportSymptom Distress ScaleDose chemotherapyBreast cancerMarrow supportSexual functioningMajority of patientsBreast cancer patientsLong-term outcomesTreatment of patientsMore yearsFLIC scoresTransplant supportIndex cancerRecurrent diseaseAssessment of qualityMedian timeCancer patientsSexual functionClinical trialsSevere symptoms
1996
Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.
Chu L, Sutton LM, Peterson BL, Havlin KA, Winer EP. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. The Journal Of Infusional Chemotherapy 1996, 6: 211-6. PMID: 9229318.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerSymptom Distress ScaleFunctional Living Index-CancerFirst-line settingFirst-line therapyBreast cancerContinuous infusionDisease progressionPrevious phase II studyRefractory metastatic breast cancerAdequate bone marrowContinuous infusion fluorouracilGrade 3 mucositisECOG performance statusMedian overall survivalObjective response ratePhase II studyContinuous intravenous infusionQuality of lifeEvaluable diseaseFLIC scoresInfusion fluorouracilMeasurable diseasePrior chemotherapyIndex cancer